Peer-Reviewed Research

    Clinical
    Studies

    NostraBiome's published and ongoing clinical research — advancing the understanding and treatment of complex conditions through rigorous multi-omics science: genomics, microbiome, metabolomics and clinical biomarkers.

    Dedicated to integrating multi-omic intelligence into everyday clinical practice, with the ultimate aim of improving patient outcomes and quality of life.

    4

    Peer-reviewed published studies

    10,000+

    Users — 1,200+ in clinical studies

    358

    Participants in the refractory IBD study

    85%+

    hs-CRP / calprotectin reduction — refractory IBD study

    "Our goal is improving clinical outcomes through a personalized reading of each individual's unique multi-omic signature."

    Our Technology

    Three layers of intelligence

    Biological Intelligence

    We read your biology as a system — DNA, microbiome, blood biomarkers and metabolism analyzed together, not in isolation.

    Human Intelligence

    Expert clinicians validate complex cases and provide deeper support when needed.

    Artificial Intelligence

    NostraAI continuously evolves by integrating the latest scientific research, medical discoveries, and groundbreaking studies.

    Published Research

    Peer-reviewed clinical studies

    Our research is published in leading scientific journals, validating multi-omic, AI-guided personalization across digestive, oncology and metabolic care.

    01Biomedicines — MDPI2025

    Introducing a Novel Personalized Microbiome-Based Treatment for Inflammatory Bowel Disease

    Results from NostraBiome's Internal Validation Study

    This study evaluates the clinical efficacy of personalized microbiome modulation (PMM) — an AI-driven intervention designed to restore microbial balance and improve key treatment outcomes such as symptom control and remission rates in IBD patients.

    Symptom control & remission rates improved significantly
    Inflammatory bowel diseaseMicrobiomePersonalized medicineAI-driven therapyFecal calprotectin
    Read full study
    Methods summary (PDF)
    02Microorganisms — MDPI2025

    Personalized Microbiome Modulation to Improve Clinical Outcomes in Pediatric Inflammatory Bowel Disease

    A Multi-Omics and Interventional Approach

    This study investigates the impact of microbiome-targeted interventions in pediatric IBD by integrating multi-omics analysis — metagenomics, metabolomics, transcriptomics, and clinical biomarkers — to identify microbial dysbiosis patterns and therapeutic targets.

    Multi-omics approach in pediatric patients
    Pediatric IBDGut microbiomeMulti-omicsDietary interventionProbiotic supplementation
    Read full study
    Methods summary (PDF)
    03International Journal of Molecular Sciences — MDPI2025

    AI-Guided Multi-Omic Microbiome Modulation Improves Clinical and Inflammatory Outcomes in Refractory IBD

    A Real-World Study

    This study evaluated a three-month, AI-guided, multi-omic personalized microbiome modulation program in adults with treatment-refractory IBD. Baseline stool metagenomic sequencing, blood biomarkers, micronutrient panels, and clinical data were integrated through an AI platform to generate individualized plans combining dietary adjustments, targeted synbiotics, selective antimicrobials, and micronutrient correction. Across 358 participants, stool frequency decreased substantially, urgency and rectal bleeding resolved in most patients, and over 70% reported a 'much improved' overall condition. Inflammatory biomarkers showed marked normalization, with reductions in hs-CRP and fecal calprotectin observed in over 85% of cases.

    358 participants — 70%+ reported 'much improved' condition
    Multi-omicsAI-guided therapyImmunometabolismShort-chain fatty acidsMicrobiome–immune interactionsPersonalized medicine
    Read full study
    Methods summary (PDF)
    04Cancers — MDPI2025

    AI-Guided Personalized Gut Microbiome Modulation for Persistent Secondary Gastrointestinal Symptoms in Oncology Patients

    Clinical Efficacy and Biological Correlates from a Prospective Validation Study

    Many cancer patients continue to experience long-lasting digestive problems — diarrhea, bloating, and abdominal discomfort — even after completing treatment. This study evaluated a personalized approach using AI to analyze each patient's microbiome, clinical data, and laboratory results to generate individualized dietary and supplement recommendations. After three months, most patients showed clear improvement in bowel habits and overall energy levels, accompanied by favorable shifts in beneficial gut bacteria (notably Bifidobacterium longum) and related metabolic markers. Findings suggest personalized microbiome modulation is a promising strategy for improving long-term quality of life in cancer survivors.

    Improved bowel habits & energy in cancer survivors at 3 months
    Cancer survivorshipGastrointestinal toxicityGut microbiomeArtificial intelligenceBifidobacterium longumPrecision supportive care
    Read full study
    Methods summary (PDF)

    Reviewing this as a clinician or R&D team?

    Study design, endpoint definitions, bias and confounding, and how the model is validated — answered directly, including where our evidence is weaker than a randomised trial.

    Read the research FAQ
    Areas of Focus

    Where we're making an impact

    Inflammatory Bowel Disease

    IBD, ulcerative colitis, Crohn's disease — multi-omic profiling (metagenomics, blood biomarkers, metabolomics) translated into personalized protocols for lasting remission.

    85%+ biomarker normalization

    Metabolic Health

    Understanding glucose regulation, weight change, energy and treatment response through integrated metabolic, microbial, genetic and clinical signals.

    Personalized metabolic support

    Oncology

    Immunotherapy response and chemotherapy side-effect reduction, including survivorship care — guided by integrated genomic, microbial and blood biomarker signals.

    Enhanced treatment tolerance

    Oral Health & Chronic Inflammation

    Mapping systemic inflammation across the oral–gut axis, immune markers and metabolic panels.

    Systemic inflammation reduction

    "We build the future that reveals the intelligence of nature — and with NostraBiome we reverse engineer it to our advantage."

    Calin Popescu — CEO & Founder

    NostraAI Platform

    Never stops learning

    NostraAI, our intelligent engine, continuously evolves by integrating the latest scientific research, medical discoveries, and groundbreaking studies. Our own insights and findings further refine the algorithms, unlocking new frontiers of knowledge and innovation.

    DNA & biological new learnings
    Artificial intelligence integration
    Real-time pattern detection
    Personalized protocol evolution

    Science-backed.
    Personalized for you.

    Join 10,000+ users — including 1,200+ in documented clinical studies — already benefiting from multi-omics precision health.